本文關鍵詞： HCC 計算機輔助藥物設計 增殖抑制 單克隆篩選 Western blot　出處：《重慶理工大學》2017年碩士論文　論文類型：學位論文

【摘要】：研究背景肝癌是最常見且死亡率很高的惡性腫瘤之一,高居全球惡性腫瘤發(fā)病率第五位,中國癌癥發(fā)病順位第二位,嚴重威脅人類健康和生命。射頻消融、化療、手術切除、肝移植等是目前肝癌常用的治療方法,然而,這些常用的治療方法雖然可以治療局部病灶,但患者術后易復發(fā),并且對放療、化療易產生耐藥性,預后很差。分子靶向抗腫瘤藥物在提高療效等方面具有一定的優(yōu)越性,這種藥物具有靶向分布特征,可通過減少給藥劑量和次數(shù)來降低藥物在全身各組織的分布,從而降低傳統(tǒng)藥物的全身性毒副作用并提高藥物的治療效率。所以,肝癌分子靶向藥物的開發(fā)在抑制肝癌腫瘤增殖、延緩復發(fā)和轉移等方面均有重要的意義。沉默信息調節(jié)因子1(silent information regulator1,SIRT1)是一類依賴于煙酰胺腺嘌呤二核苷酸(NAD+)的第Ⅲ類組蛋白去乙�；浮⑴c細胞能量代謝、應激耐受、分化、衰老和凋亡等多種生理活動。據(jù)文獻報道,SIRT1在肝癌組織中的表達水平明顯增高,本實驗室通過虛擬篩選篩出了小分子化合物Tipranavir,通過通過體內外抗肝癌活性實驗,發(fā)現(xiàn)Tipranavir對肝癌細胞有很強的增殖抑制作用。而據(jù)藥典和文獻報道,藥物Tipranavir是CYP3A4肝藥酶的抑制劑。是肝臟中最多的肝藥酶。這些前期的研究結果為我們提供了思路,Tipranavir究竟是作用于SIRT1還是作用于CYP3A4,抑或是兩者協(xié)同作用而導致對肝癌細胞增殖抑制,還是說可能還存在其他的作用靶點,是一個值得我們去深入探討的問題。研究目的基于Sybyl2.1平臺的Surflex-Dock模塊和Discovery Studio3.0平臺的Ligand Fit docking模塊通過對接研究、比較Tipranavir分別和SIRT1晶體和CYP3A4的對接結果。構建肝癌細胞HepG2 SIRT1敲除細胞、肝癌細胞HepG2 CYP3A4敲除細胞,并進行單克隆篩選篩出單克隆敲除株。通過細胞實驗驗證Tipranavir對肝癌細胞敲除前后的抑制率變化,為研究Tipranavir抑制HCC的通路奠定基礎。研究方法1.基于CADD平臺將Tipranavir與SIRT1和CYP3A4蛋白晶體結構進行對接。2.構建HepG2細胞SIRT1和CYP3A4分別敲除細胞株及驗證。3.篩選敲除細胞的單克隆細胞株及驗證。4.CCK-8增殖抑制法檢測Tipranavir對HepG2及其敲除細胞的增殖抑制率。5.以Tipranavir為配體基于id Target平臺和Pharm Mapper平臺通過反向分子對接查找肝癌相關的靶蛋白。研究成果本課題通過體外CCK-8增殖抑制法檢測Tipranavir對HepG2及其敲除細胞的增殖抑制率,得出Tipranavir對SIRT1和CYP3A4敲除細胞均有一定的增殖抑制作用,但不明顯。Tipranavir對正常肝細胞的增殖抑制作用遠低于肝癌細胞。
[Abstract]:Background Hepatocellular carcinoma is one of the most common malignant tumors with high mortality rate, which ranks 5th in the world and ranks second in China, which is a serious threat to human health and life, radiofrequency ablation, chemotherapy and surgical resection. Liver transplantation is a common treatment for liver cancer at present. However, although these commonly used treatments can treat local lesions, patients are prone to relapse after operation, and are prone to develop drug resistance to radiotherapy and chemotherapy. The prognosis is very poor. Molecular targeted antitumor drugs have some advantages in improving the curative effect and so on. This kind of drug has the characteristics of targeted distribution, which can reduce the distribution of drugs in all tissues of the body by reducing the dosage and times of administration. Therefore, the development of molecular targeting drugs for liver cancer is to inhibit the proliferation of liver cancer tumors. Silent information regulator1SIRT1) is a kind of histone deacetylase dependent on nicotinamide adenine dinucleotide (NAD). It is involved in cell energy metabolism, stress tolerance and differentiation. It was reported that the expression level of SIRT1 in hepatocellular carcinoma was significantly increased. The small molecular compound Tipranavirus was screened by virtual screening in our laboratory, and the anti-hepatoma activity was tested in vivo and in vitro. It was found that Tipranavir had a strong inhibitory effect on the proliferation of hepatoma cells, and according to pharmacopoeia and literature reports, The drug Tipranavir is the inhibitor of liver drug enzyme of CYP3A4. It is the most common hepatic drug enzyme in the liver. These preliminary results provide us with some ideas as to whether Tipranavir acts on SIRT1, CYP3A4, or the synergistic effect of both on inhibiting the proliferation of hepatoma cells. Or that there may still exist other targets, which is a problem worthy of further discussion. The purpose of this study is to study the Surflex-Dock module based on Sybyl2.1 platform and the Ligand Fit docking module of Discovery Studio3.0 platform through docking. The docking results of Tipranavir with SIRT1 crystal and CYP3A4 were compared. HepG2 SIRT1 knockout cells and HepG2 CYP3A4 knockout cells were constructed. The inhibition rate of Tipranavir on hepatoma cells before and after knockout was verified by cell experiments. Methods 1. The crystal structure of Tipranavir with SIRT1 and CYP3A4 proteins was docked based on CADD platform. 2. HepG2 cell SIRT1 and CYP3A4 knockout cell lines were constructed and verified. 3. Single gram of knockout cells was screened. 2. The proliferation inhibition rate of Tipranavir on HepG2 and its knockout cells was determined by CCK-8 proliferation inhibition assay. 5. Tipranavir as ligand was used as ligand to find the target proteins related to HCC by reverse molecular docking based on id Target platform and Pharm Mapper platform. In this study, the inhibitory rate of Tipranavir on HepG2 and its knockout cells was detected by CCK-8 proliferation inhibition assay in vitro. The results showed that Tipranavir could inhibit the proliferation of both SIRT1 and CYP3A4 knockout cells, but the inhibitory effect of Tipranavir on normal hepatocytes was much lower than that on HCC cells.
【學位授予單位】：重慶理工大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R96

【參考文獻】

相關期刊論文 前8條

1 張婷;王華華;車萌;張嚴;;基于反向找靶的抗腫瘤活性研究[J];計算機與應用化學;2016年03期

2 萬靜枝;袁丁;王婷;;調節(jié)Sirt1的microRNA的研究進展[J];中國臨床藥理學與治療學;2013年12期

3 李凌娟;李春鳳;胡慶亮;;SIRT1與衰老相關疾病的研究進展[J];綠色科技;2013年07期

4 范勝軍;李學軍;;反向分子對接-藥物靶點發(fā)現(xiàn)和確認的新途徑[J];生理科學進展;2012年05期

5 劉瑞環(huán);寧澄清;畢艷靜;余聶芳;;SIRT1抑制劑的研究進展[J];中南藥學;2012年08期

6 趙志強;毛文瓊;;SIRT1與腫瘤發(fā)生[J];臺州學院學報;2011年06期

7 陳厚早;張祝琴;韋玉生;劉德培;;去乙酰化酶SIRT1的研究進展[J];中國醫(yī)學科學院學報;2007年03期

8 ;Immunohistochemical detection of HCV infection in patients with hepatocellular carcinoma and other liver diseases[J];世界胃腸病學雜志;1998年01期

相關博士學位論文 前1條

1 宋世俊;SIRT1在肝細胞癌中的表達和臨床意義及其和YAP2與P53之間的關系[D];吉林大學;2014年

，

本文編號：1504163